Accelerating drug development and patient access to global medicines in Japan
Accelerating drug development and patient access to global medicines in Japan
Today there is a growing drug loss in Japan and Asia in which innovative medicines accessible to patients in the US and Europe are not available in Japan and Asia.
One reason for this is the fact that more and more new medicines being approved in the US and Europe are developed and commercialized by emerging biopharma companies without a presence in Japan.
Accelys partners with these emerging biopharma companies to bring their innovative products to Japan and accelerate their development, commercialization and access for patients.
OUR TEAM
A platform of over 20 professionals specializing in clinical development, regulatory sciens, CMC and drug supply, quality and safety, pricing and marketing, and commercial launch of new medicines in Japan.
Our Partners
Aculys
Tackling the Social Issues in Neurology Head-on
Hepalys
Improving Access to Medicine for Liver Disease
Renalys
Catalyst to Access Novel Therapies for Asian Patients with Renal Disease
News
